Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.49 |
| ▸ | GAK | O14976 | 2/20 | 0.47 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.47 |
| ▸ | COQ8A | Q8NI60 | 2/20 | 0.47 |
| ▸ | NLK | Q9UBE8 | 2/20 | 0.47 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.43 |
| ▸ | TUBB | P07437 | 1/20 | 0.43 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.43 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.43 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.43 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.43 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.43 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.43 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.43 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.43 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.43 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.43 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.43 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.43 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2905022 | 0.87 | GAK (0.47) | MAOAGAKRIPK2COQ8ANLK | |
| SCHEMBL7337530 | 0.85 | AR (0.46) | GAKRIPK2COQ8ANLKAR | |
| SCHEMBL10786809 | 0.83 | NCEH1 (0.40) | MAOAGAKRIPK2COQ8ANLK | |
| SCHEMBL28313760 | 0.78 | GAK (0.43) | GAKRIPK2COQ8ANLKAR | |
| SCHEMBL7341254 | 0.77 | AR (0.56) | ARCACNA1GCACNA1BHPGDS | |
| SCHEMBL14421959 | 0.75 | MAOA (0.54) | MAOATUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL7723749 | 0.75 | AR (0.50) | GAKRIPK2COQ8ANLKAR | |
| SCHEMBL6100006 | 0.75 | ACHE (0.57) | GAKRIPK2COQ8ANLKAR | |
| SCHEMBL27519630 | 0.74 | MAOA (0.53) | MAOATUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL18754324 | 0.73 | AR (0.49) | GAKRIPK2COQ8ANLKAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1400510-B1 | CYCLIC DIAMINE COMPOUNDS HAVING FUSED-RING GROUPS | KOWA CO (JP) | 2010-08-18 | — | — | EP | disclosed |
| US-7135473-B2 | Cyclic diamine compound with condensed-ring groups | KOWA CO., LTD. (JP) | 2006-11-14 | — | — | US | disclosed |
| CN-1281585-C | Cyclic diamine compounds having fused-ring groups | KOWA CO (JP) | 2006-10-25 | — | — | CN | disclosed |
| CN-1599717-A | Cyclic diamine compounds having fused-ring groups | KOWA CO (JP) | 2005-03-23 | — | — | CN | disclosed |
| US-20040058913-A1 | Cyclic diamine compound with condensed-ring groups | KOWA CO., LTD. (JP) | 2004-03-25 | — | — | US | disclosed |
| EP-1400510-A1 | CYCLIC DIAMINE COMPOUNDS HAVING FUSED-RING GROUPS | Kowa Co., Ltd. (JP) | 2004-03-24 | — | — | EP | disclosed |
| US-6632810-B2 | Such as N,N'-bis((5,6,7-trimethoxynaphthalen-2-yl)methyl) piperazine, which has inhibitory effects on cell adhesion, for treatment of allergy, asthma, rheumatism, arteriosclerosis, and inflammation | KOWA CO., LTD. (JP) | 2003-10-14 | — | — | US | disclosed |
| US-20030060461-A1 | Cyclic diamine compound with condensed-ring groups | KOWA CO., LTD. (JP) | 2003-03-27 | — | — | US | disclosed |
| US-20010049374-A1 | Urokinase inhibitors | STEELE ANDREW W (US) | 2001-12-06 | — | — | US | disclosed |
| US-6284796-B1 | NAPHTHAMIDINE COMPOUNDS | ABBOTT LABORATORIES | 2001-09-04 | — | — | US | disclosed |
| US-6258822-B1 | ENZYME INHIBITORS OF NAPHTHALENE AMIDINE COMPOUNDS | ABBOTT LABORATORIES | 2001-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058913-A1 | Cyclic diamine compound with condensed-ring groups | HRH4, HRH3, HRH1 | MAOA 1802/4885GAK 2803/4885RIPK2 2443/4885 |
| US-20030060461-A1 | Cyclic diamine compound with condensed-ring groups | HRH4, HRH3, HRH1 | MAOA 1802/4885GAK 2803/4885RIPK2 2443/4885 |
| US-20010049374-A1 | Urokinase inhibitors | SERPINE1, PLAU, SERPINB1 | MAOA 743/4885GAK 1645/4885RIPK2 2070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.